Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
Article Details
- CitationCopy to clipboard
Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L
Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
Neurol Clin. 2018 May;36(2):293-310. doi: 10.1016/j.ncl.2018.01.004.
- PubMed ID
- 29655451 [ View in PubMed]
- Abstract
Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.
DrugBank Data that Cites this Article
- Drugs